301230 泓博医药
已收盘 08-06 15:00:00
资讯
新帖
简况
泓博医药(301230)7月31日股东户数2.44万户,较上期减少7.79%
证券之星 · 08-03
泓博医药(301230)7月31日股东户数2.44万户,较上期减少7.79%
泓博医药:截至2026年7月31日股东户数为24,436户
证券之星 · 08-03
泓博医药:截至2026年7月31日股东户数为24,436户
泓博医药:2025年度海外业务销售收入占主营业务收入的69.22%
证券之星 · 08-03
泓博医药:2025年度海外业务销售收入占主营业务收入的69.22%
泓博医药:临床Ⅰ期7个、临床Ⅱ期1个
证券之星 · 07-30
泓博医药:临床Ⅰ期7个、临床Ⅱ期1个
泓博医药:CADD/AIDD技术平台已累计为104个新药项目提供技术支持
证券之星 · 07-30
泓博医药:CADD/AIDD技术平台已累计为104个新药项目提供技术支持
7月30日泓博医药跌6.47%,长城消费增值混合A基金重仓该股
证券之星 · 07-30
7月30日泓博医药跌6.47%,长城消费增值混合A基金重仓该股
泓博医药:关于减肥药(含GLP-1相关)领域,公司具备丰富的技术服务能力
证券之星 · 07-30
泓博医药:关于减肥药(含GLP-1相关)领域,公司具备丰富的技术服务能力
7月24日泓博医药跌5.47%,长城消费增值混合A基金重仓该股
证券之星 · 07-24
7月24日泓博医药跌5.47%,长城消费增值混合A基金重仓该股
股市必读:泓博医药(301230)7月23日董秘有最新回复
证券之星 · 07-24
股市必读:泓博医药(301230)7月23日董秘有最新回复
泓博医药:目前公司无相关的合作与自研管线
证券之星 · 07-23
泓博医药:目前公司无相关的合作与自研管线
7月17日泓博医药跌16.34%,长城消费增值混合A基金重仓该股
证券之星 · 07-17
7月17日泓博医药跌16.34%,长城消费增值混合A基金重仓该股
7月15日泓博医药涨5.06%,长城消费增值混合A基金重仓该股
证券之星 · 07-15
7月15日泓博医药涨5.06%,长城消费增值混合A基金重仓该股
股市必读:泓博医药(301230)7月10日董秘有最新回复
证券之星 · 07-13
股市必读:泓博医药(301230)7月10日董秘有最新回复
7月10日泓博医药涨13.13%,长城消费增值混合A基金重仓该股
证券之星 · 07-10
7月10日泓博医药涨13.13%,长城消费增值混合A基金重仓该股
7月8日泓博医药跌5.85%,长城消费增值混合A基金重仓该股
证券之星 · 07-08
7月8日泓博医药跌5.85%,长城消费增值混合A基金重仓该股
泓博医药:本次权益分派将在股东会审议通过之日起两个月内实施完毕
证券之星 · 07-08
泓博医药:本次权益分派将在股东会审议通过之日起两个月内实施完毕
泓博医药:截至2026年6月30日股东户数为21,845户
证券之星 · 07-08
泓博医药:截至2026年6月30日股东户数为21,845户
7月7日泓博医药跌6.62%,长城消费增值混合A基金重仓该股
证券之星 · 07-07
7月7日泓博医药跌6.62%,长城消费增值混合A基金重仓该股
7月1日泓博医药涨6.89%,长城消费增值混合A基金重仓该股
证券之星 · 07-01
7月1日泓博医药涨6.89%,长城消费增值混合A基金重仓该股
6月29日泓博医药涨11.97%,长城消费增值混合A基金重仓该股
证券之星 · 06-29
6月29日泓博医药涨11.97%,长城消费增值混合A基金重仓该股
加载更多
公司概况
公司名称:
上海泓博智源医药股份有限公司
所属行业:
研究和试验发展
上市日期:
2022-11-01
主营业务:
上海泓博智源医药股份有限公司的主营业务是药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。公司的主要产品是药物化学、合成化学、药物代谢动力学、工艺化学、工艺开发、药学研究、定制化生产、自主产品生产。
发行价格:
40.00
{"stockData":{"symbol":"301230","market":"SZ","secType":"STK","nameCN":"泓博医药","latestPrice":27.02,"timestamp":1785999819000,"preClose":27.31,"halted":0,"volume":10763133,"delay":0,"changeRate":-0.0106,"floatShares":163000000,"shares":181000000,"eps":0.2548,"marketStatus":"已收盘","change":-0.29,"latestTime":"08-06 15:00:00","open":27.38,"high":27.93,"low":26.78,"amount":293000000,"amplitude":0.0421,"askPrice":27.04,"askSize":1,"bidPrice":27.02,"bidSize":364,"shortable":0,"etf":0,"ttmEps":0.2548,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786066200000},"marketStatusCode":5,"adr":0,"adjPreClose":27.31,"symbolType":"stock","openAndCloseTimeList":[[1785979800000,1785987000000],[1785992400000,1785999600000]],"highLimit":30.04,"lowLimit":24.58,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":180941126,"isCdr":false,"pbRate":4.8,"roa":"--","peRate":106.043956,"roe":"2.34%","epsLYR":0.25,"committee":0.908745,"marketValue":4889000000,"turnoverRate":0.0661,"status":1,"floatMarketCap":4397000000},"requestUrl":"/m/hq/s/301230","defaultTab":"news","newsList":[{"id":"2656327487","title":"泓博医药(301230)7月31日股东户数2.44万户,较上期减少7.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656327487","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656327487?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:45","pubTimestamp":1785750328,"startTime":"0","endTime":"0","summary":"证券之星消息,近日泓博医药披露,截至2026年7月31日公司股东户数为2.44万户,较7月20日减少2065.0户,减幅为7.79%。在医疗服务行业个股中,泓博医药股东户数低于行业平均水平,截至7月31日,医疗服务行业平均股东户数为4.92万户。从股价来看,2026年7月20日至2026年7月31日,泓博医药区间跌幅为12.43%,在此期间股东户数减少2065.0户,减幅为7.79%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300024131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656293033","title":"泓博医药:截至2026年7月31日股东户数为24,436户","url":"https://stock-news.laohu8.com/highlight/detail?id=2656293033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656293033?lang=zh_cn&edition=full","pubTime":"2026-08-03 15:37","pubTimestamp":1785742674,"startTime":"0","endTime":"0","summary":"证券之星消息,泓博医药(301230)08月03日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司最新股东人数是多少泓博医药回复:尊敬的投资者您好!根据中登公司下发的股东名册,截至2026年7月31日(交易日),公司的股东户数为24,436户。感谢关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300014973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656329536","title":"泓博医药:2025年度海外业务销售收入占主营业务收入的69.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656329536","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656329536?lang=zh_cn&edition=full","pubTime":"2026-08-03 15:37","pubTimestamp":1785742669,"startTime":"0","endTime":"0","summary":"投资者提问:公司2025年海外收入占比69.22%,请具体披露:2026年上半年海外收入占比变化及主要区域分布;美国《生物安全法案》温和落地后,北美Top 20药企中与公司有CDMO/CRO合作的客户数量及订单金额区间;欧洲/日本市场拓展进度。2025年度,公司海外业务销售收入占主营业务收入的69.22%,业务覆盖美国、印度及欧洲部分国家和地区。2026年上半年具体经营数据及客户、订单情况属于商业敏感及未公开经营信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300014959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655870917","title":"泓博医药:临床Ⅰ期7个、临床Ⅱ期1个","url":"https://stock-news.laohu8.com/highlight/detail?id=2655870917","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655870917?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:52","pubTimestamp":1785415952,"startTime":"0","endTime":"0","summary":"证券之星消息,泓博医药07月30日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的领导您好,公司提及CADD/AIDD平台已累计服务104个新药项目、8个进入临床、53家客户 ——其中是否有项目进入临床II期或III期?截至2025年底,公司CADD/AIDD平台已累计为104个新药项目提供技术支持,其中8个项目进入临床实验阶段,具体为:临床Ⅰ期7个、临床Ⅱ期1个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000037425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655870912","title":"泓博医药:CADD/AIDD技术平台已累计为104个新药项目提供技术支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2655870912","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655870912?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:52","pubTimestamp":1785415952,"startTime":"0","endTime":"0","summary":"投资者提问:董秘你好,2025年全年及2026年一季度,CADD/AIDD技术平台赋能的项目中,有多少形成了实际的合同订单?截至2025年12月底,公司CADD/AIDD技术平台已累计为104个新药项目提供技术支持,其中8个项目已进入临床实验阶段。平台服务客户总数达53家,涵盖国内外多家创新药企与生物技术公司。公司的CADD/AIDD平台是赋能公司早期药物研发的核心技术手段,已深度融入公司现有的研发服务体系中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000037426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655822295","title":"7月30日泓博医药跌6.47%,长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655822295","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655822295?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:59","pubTimestamp":1785401945,"startTime":"0","endTime":"0","summary":"证券之星消息,7月30日泓博医药跌6.47%创60日新低,收盘报22.55元,换手率6.2%,成交量10.1万手,成交额2.35亿元。重仓泓博医药的公募基金请见下表:根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000026392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655826047","title":"泓博医药:关于减肥药(含GLP-1相关)领域,公司具备丰富的技术服务能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2655826047","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655826047?lang=zh_cn&edition=full","pubTime":"2026-07-30 15:30","pubTimestamp":1785396624,"startTime":"0","endTime":"0","summary":"证券之星消息,泓博医药(301230)07月30日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的领导您好。市场高度关注减肥药产业链,公司是否考虑发布专项自愿性信息披露公告,向市场详细介绍在GLP-1等热门赛道的技术储备与订单进展?泓博医药回复:尊敬的投资者,您好!关于减肥药(含GLP-1相关)领域,公司具备丰富的技术服务能力,已为多个客户提供新药研发技术服务,相关业务进展均按正常商业节奏推进。由于公司与合作客户均签署了保密协议,需严格履行保密义务,无法透露具体的项目信息。感谢关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000018991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653236700","title":"7月24日泓博医药跌5.47%,长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653236700","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653236700?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:54","pubTimestamp":1784883273,"startTime":"0","endTime":"0","summary":"证券之星消息,7月24日泓博医药跌5.47%,收盘报24.7元,换手率5.91%,成交量9.62万手,成交额2.43亿元。重仓泓博医药的公募基金请见下表:根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400029030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653672224","title":"股市必读:泓博医药(301230)7月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2653672224","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653672224?lang=zh_cn&edition=full","pubTime":"2026-07-24 01:18","pubTimestamp":1784827095,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘,泓博医药报收于26.13元,下跌1.4%,换手率6.64%,成交量10.81万手,成交额2.84亿元。董秘最新回复投资者: 尊敬的董秘你好,请问公司有没有为武田提供该药物CRO/CDMO研发生产服务?目前公司无相关的合作与自研管线。交易信息汇总资金流向7月23日主力资金净流出738.81万元;游资资金净流入1578.41万元;散户资金净流出839.6万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400001027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653717451","title":"泓博医药:目前公司无相关的合作与自研管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2653717451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653717451?lang=zh_cn&edition=full","pubTime":"2026-07-23 16:03","pubTimestamp":1784793790,"startTime":"0","endTime":"0","summary":"证券之星消息,泓博医药(301230)07月23日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘你好,请问公司有没有为武田提供该药物CRO/CDMO研发生产服务?公司有没有OX2R激动剂制药自研管线?泓博医药回复:尊敬的投资者您好!目前公司无相关的合作与自研管线。感谢关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300029774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652095104","title":"7月17日泓博医药跌16.34%,长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652095104","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652095104?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:00","pubTimestamp":1784278809,"startTime":"0","endTime":"0","summary":"证券之星消息,7月17日泓博医药跌16.34%,收盘报28.72元,换手率19.93%,成交量25.03万手,成交额7.61亿元。重仓泓博医药的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651455881","title":"7月15日泓博医药涨5.06%,长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651455881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651455881?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:37","pubTimestamp":1784104652,"startTime":"0","endTime":"0","summary":"证券之星消息,7月15日泓博医药涨5.06%,收盘报42.15元,换手率17.08%,成交量21.45万手,成交额9.1亿元。重仓泓博医药的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500031244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651663701","title":"股市必读:泓博医药(301230)7月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651663701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651663701?lang=zh_cn&edition=full","pubTime":"2026-07-13 02:10","pubTimestamp":1783879821,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘,泓博医药报收于40.16元,上涨13.13%,换手率14.53%,成交量18.24万手,成交额7.1亿元。董秘最新回复投资者: 你好,请问截至6月30日股东人数,谢谢董秘: 尊敬的投资者您好!根据中登公司下发的股东名册,截至2026年6月30日(交易日),公司的股东户数为21,845户。交易信息汇总资金流向7月10日主力资金净流入383.7万元,占总成交额0.0%;游资资金净流出4617.27万元,占总成交额0.0%;散户资金净流入4233.57万元,占总成交额0.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300001093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650183091","title":"7月10日泓博医药涨13.13%,长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650183091","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650183091?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:37","pubTimestamp":1783672641,"startTime":"0","endTime":"0","summary":"证券之星消息,7月10日泓博医药涨13.13%,收盘报40.16元,换手率14.53%,成交量18.24万手,成交额7.1亿元。重仓泓博医药的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000029319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649961118","title":"7月8日泓博医药跌5.85%,长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649961118","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649961118?lang=zh_cn&edition=full","pubTime":"2026-07-08 16:45","pubTimestamp":1783500311,"startTime":"0","endTime":"0","summary":"证券之星消息,7月8日泓博医药跌5.85%,收盘报34.77元,换手率6.82%,成交量8.56万手,成交额3.08亿元。重仓泓博医药的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800029603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649956908","title":"泓博医药:本次权益分派将在股东会审议通过之日起两个月内实施完毕","url":"https://stock-news.laohu8.com/highlight/detail?id=2649956908","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649956908?lang=zh_cn&edition=full","pubTime":"2026-07-08 08:48","pubTimestamp":1783471691,"startTime":"0","endTime":"0","summary":"证券之星消息,泓博医药(301230)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问:2025年分红计划四月份就通过了,为什么到现在还没执行?预计什么时候会有结果?泓博医药回复:尊敬的投资者您好!《关于公司2025年度利润分配方案的议案》已于2026年5月19日股东会审议通过,本次权益分派将在股东会审议通过之日起两个月内实施完毕,当前权益分派相关工作正在积极推进,敬请留意近期公告。感谢关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800008341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649956577","title":"泓博医药:截至2026年6月30日股东户数为21,845户","url":"https://stock-news.laohu8.com/highlight/detail?id=2649956577","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649956577?lang=zh_cn&edition=full","pubTime":"2026-07-08 08:39","pubTimestamp":1783471157,"startTime":"0","endTime":"0","summary":"证券之星消息,泓博医药(301230)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问:请问董秘,截止到2026年07月02日,公司股东户数是多少?泓博医药回复:尊敬的投资者您好!根据中登公司下发的股东名册,截至2026年6月30日(交易日),公司的股东户数为21,845户。感谢关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800008259.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649882799","title":"7月7日泓博医药跌6.62%,长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649882799","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649882799?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:42","pubTimestamp":1783413725,"startTime":"0","endTime":"0","summary":"证券之星消息,7月7日泓博医药跌6.62%,收盘报36.93元,换手率7.68%,成交量9.64万手,成交额3.63亿元。重仓泓博医药的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700027737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648516467","title":"7月1日泓博医药涨6.89%,长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648516467","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648516467?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:55","pubTimestamp":1782896137,"startTime":"0","endTime":"0","summary":"证券之星消息,7月1日泓博医药涨6.89%,收盘报39.38元,换手率12.09%,成交量15.19万手,成交额5.73亿元。重仓泓博医药的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647322241","title":"6月29日泓博医药涨11.97%,长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647322241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647322241?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:54","pubTimestamp":1782723269,"startTime":"0","endTime":"0","summary":"证券之星消息,6月29日泓博医药涨11.97%,收盘报38.72元,换手率10.21%,成交量12.82万手,成交额4.82亿元。重仓泓博医药的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786027549576,"stockEarnings":[{"period":"1week","weight":0.1327},{"period":"1month","weight":-0.1007},{"period":"3month","weight":-0.1848},{"period":"6month","weight":-0.2269},{"period":"1year","weight":-0.0561},{"period":"ytd","weight":0.1933}],"compareEarnings":[{"period":"1week","weight":0.013},{"period":"1month","weight":-0.0403},{"period":"3month","weight":-0.0722},{"period":"6month","weight":-0.046},{"period":"1year","weight":0.0721},{"period":"ytd","weight":-0.0228}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海泓博智源医药股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"24436人(较上一季度减少7.79%)","perCapita":"6660股","listingDate":"2022-11-01","address":"上海市浦东新区庆达路315号23幢","registeredCapital":"18094万元","survey":" 上海泓博智源医药股份有限公司的主营业务是药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。公司的主要产品是药物化学、合成化学、药物代谢动力学、工艺化学、工艺开发、药学研究、定制化生产、自主产品生产。","listedPrice":40},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泓博医药,301230,泓博医药股票,泓博医药股票老虎,泓博医药股票老虎国际,泓博医药行情,泓博医药股票行情,泓博医药股价,泓博医药股市,泓博医药股票价格,泓博医药股票交易,泓博医药股票购买,泓博医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}